After scathing accusations of skimping on due diligence, as well as other feedback to my article on trying to use an ‘AI ...

To our knowledge, this study is the first to apply deep learning models that can, beyond diagnosis, identify molecular subtypes and predict outcomes in a single brain tumour entity (meningioma) using ...

As clinical trials grow increasingly complex and multi-modal, the pharmaceutical industry is pivoting toward AI-driven agentic orchestrators and lakehouse architectures to untangle disparate data ...